Senores Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 43.8% YoY, showing strong momentum
- Company has consistently been profitable over the last 5 years
- Working capital cycle has improved - days down from 442 to 224
- Company comfortably covers its interest (7.4x coverage)
- Institutional investors have been accumulating - FII+DII up 3.2pp
- Attractively priced for its growth - PEG of 0.4
CONS
- Receivables are growing faster than sales - a possible quality concern
- A large part of profit comes from other income (29.6% of PBT)
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.05x)
- Operating cash flow has been negative in recent years
- Equity base is being diluted - shares outstanding up 369.2%
- Free cash flow has been persistently negative
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SENORES | 1467.45 | 53.48 | 6758.13 | 0.00 | 30.45 | 43.77 | 180.21 | 38.30 | 15.66 | 29.83 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 79 | 102 | 80 | 98 | 103 | 114 | 130 | 153 | 165 | 175 | 180 | |
| 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 144 | |
| Operating Profit | 15 | 22 | 20 | 21 | 26 | 19 | 26 | 41 | 44 | 47 | 37 |
| OPM % | 19.25% | 21.86% | 25.70% | 21.25% | 24.93% | 17.02% | 20.31% | 26.81% | 26.87% | 27.11% | 20.34% |
| 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 4 | 18 | 3 | |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before Tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 30.63% | 19.48% | 18.95% | 18.24% | 19.82% | 13.10% | 20.05% | 25.89% | 24.69% | 22.64% | 22.83% |
| Net Profit | 0 | 0 | 0 | 0 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| 4.01 | 8.03 | 3.39 | 3.92 | 5.04 | 3.81 | 4.60 | 6.54 | 7.29 | 7.96 | 6.61 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 14 | 35 | 215 | 398 | 633 | 674 | |
| 12 | 23 | 173 | 309 | 464 | 504 | |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 170 |
| OPM % | 13.78% | 35.85% | 19.38% | 22.52% | 26.61% | 25.17% |
| 0 | 4 | 3 | 19 | 47 | 30 | |
| Interest | 1 | 2 | 9 | 22 | 25 | 27 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 35 |
| Profit before Tax | 1 | 12 | 25 | 71 | 159 | 172 |
| Tax % | 13.30% | 32.19% | -31.15% | 17.33% | 23.61% | 23.98% |
| Net Profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS | 1.81 | 6.65 | 10.31 | 12.72 | 25.05 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 162%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 139%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 107%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 15%
- 3 Years:
- 17%
- Last Year:
- 14%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Minority Interest | 0 | 0 | 27 | 26 | 31 |
| 28 | 36 | 174 | 740 | 887 | |
| 15 | 59 | 238 | 293 | 327 | |
| Trade Payables | 7 | 14 | 113 | 67 | 235 |
| 0 | 12 | 24 | 36 | 77 | |
| Total Liabilities | 59 | 131 | 607 | 1,208 | 1,604 |
| 7 | 27 | 235 | 301 | 499 | |
| Capital Work in Progress | 0 | 8 | 18 | 44 | 17 |
| 15 | 16 | 0 | 0 | 4 | |
| 3 | 3 | 37 | 57 | 89 | |
| 0 | 0 | 112 | 124 | 325 | |
| Cash & Bank | 3 | 0 | 13 | 386 | 160 |
| 30 | 76 | 191 | 297 | 510 | |
| Total Assets | 59 | 131 | 607 | 1,208 | 1,604 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -10 | 0 | -26 | -46 | 62 | |
| Cash from Investing | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing | 36 | 46 | 87 | 573 | -1 |
| 2 | -3 | 7 | 98 | -60 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-11 - Senores Pharmaceuticals Limited has informed the Exchange about Successful Completion of USFDA Inspection
2026-09-04 - Senores Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to the 9th Annual General Meeting of the Company.
2026-09-03 - Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of 9th Annual General Meeting to be held on September 25, 2026
2026-08-27 - Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet
2026-08-27 - Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company
2026-08-26 - Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Viranchi Arvindbhai Shah as Non- Executive Independent Director of the company w.e.f. August 26, 2026.
2026-08-26 - Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026 ( ESOS 2026 / SCHEME )
2026-08-26 - Proposed incorporation of a Wholly Owned Subsidiary (WOS) in Mexico
2026-08-26 - Proposed incorporation of a Subsidiary Company in Canada
News
Recent coverage and analyst commentary for SENORES
Loading news…
AI Stock Analyst
Senores Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account